Percutaneous coronary intervention with drug-eluting stents or coronary artery bypass surgery in subjects with type 2 diabetes

Author： Doggrell Sheila A  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.9, 2013-06, pp. : 1269-1273

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug-Eluting Stents in Percutaneous Coronary Intervention: A Benefit-Risk Assessment

By Byrne Robert A.   Sarafoff Nikolaus   Kastrati Adnan   Schömig Albert  

Drug Safety, Vol. 32, Iss. 9, 2009-09 ,pp. : 749-770

Adis International

Access to resources Recommend Favorite

Use of Antiplatelet Therapy after Percutaneous Coronary Intervention with Bare-Metal Stents and Different Types of Drug-Eluting Stents

By  

Current Clinical Pharmacology, Vol. 8, Iss. 1, 2013-02 ,pp. : 59-66

Bentham Science Publishers

Access to resources Recommend Favorite

Drug Eluting Coronary Artery Stents

By  

Current Drug Delivery, Vol. 7, Iss. 5, 2010-12 ,pp. : 421-427

Bentham Science Publishers

Access to resources Recommend Favorite

Sirolimus: Coronary artery aneurysms following implantation of drug-eluting stents in an elderly patient: case report

By  

Reactions Weekly, Vol. 1, Iss. 1181, 2007-01 ,pp. : 34-35

Adis International

Access to resources Recommend Favorite

Optimal Duration of Antiplatelet Therapy in Recipients of Coronary Drug-Eluting Stents

By Zimarino Marco   Renda Giulia   Raffaele De Caterina  

Drugs, Vol. 65, Iss. 6, 2005-01 ,pp. : 725-732

Adis International

Access to resources Recommend Favorite